James Bauersmith

James is an experienced healthcare executive with over 20 years of experience across a variety of healthcare segments. He currently works for UPMC Enterprises as Vice President of Translational Sciences leading venture capital investments into life science companies out of a $1B fund. Before joining Enterprises, James was the Chief Strategic Officer and General Counsel of ByHeart, Inc., an infant formula company, where he led the company’s FDA strategy, managed all legal affairs and led the acquisition and set-up of the company’s manufacturing facility. Prior to his role at ByHeart, James worked in the pharmaceutical sector for over 15 years where he held a variety of leadership positions at Fresenius Kabi, where he was the SVP overseeing the company’s portfolio and marketing strategy unit, and Amneal Pharmaceuticals where he oversaw the corporate development and procurement groups and was part of the executive management team. Jamie also served as an independent Board Director for Akorn Pharmaceuticals from October 2020 to February 2023.

Before his tenure at Fresenius and Amneal, James spent 10 years practicing law, first as an attorney in New York with Haug Partners and then as in-house counsel at Teva Pharmaceuticals where he managed the company’s Hatch Waxman Patent litigations. He earned a B.S. from the University of Notre Dame, a J.D. from the Pennsylvania State University School of Law, and an M.S. of Bioscience and Biotechnology from Drexel University. He is a registered U.S. Patent Attorney and maintains an active Pennsylvania law license.